High HBV and HIV Suppression With Treatment of HIV/HBV Coinfection in B/F/TAF Studies

Rockstroh JK1, Daar ES2, Walmsley S3, Workowski K4, Orkin C5, Arribas JR6, DeJesus E7, Molina J-M8, Piontkowsky D9, Wei X9, Martin H9, Cheng A9, Barnes T10, Quirk E11

1Universität Bonn, Bonn, Germany, 2Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA, 3Toronto General Hospital, Toronto, Ontario, Canada, 4Emory University, Atlanta, GA, USA, 5Barts Health NHS Trust, The Royal London Hospital, Ambrose King Centre, London, UK, 6Hospital Universitario la Paz, Madrid, Spain, 7Orlando Immunology Center, Orlando, FL, USA, 8Hôpital Saint Louis, Paris, France, 9Gilead Sciences, Foster City, CA, USA, 10Holdsworth House, Sydney, NSW, Australia

We extend our thanks to the participants, their families, and all participating study investigators and staff. These studies were funded by Gilead Sciences, Inc.

Disclosures: Timothy Barnes is a consultant/advisor for and has received grants from Gilead Sciences, ViV Healthcare
BACKGROUND/AIMS & METHODS:

- Hepatitis B virus (HBV) is a common coinfection in HIV patients
  - Estimates range from 3 to 6 million individuals coinfected with HIV and HBV with coinfection rates up to 25%1
- Coinfection worsens morbidity and mortality synergistically
  - HIV/HBV-coinfected patients have higher HBV DNA levels, are 5 times more likely to progress to chronic HBV than HBV mono-infected patients, and have 2-3 times higher risks of cirrhosis and hepatocellular carcinoma
- Tenofovir alafenamide (TAF) is active against HBV and is approved for treatment of HBV as a single agent2,3
- Current HIV guidelines recommend TAF or tenofovir disoproxil fumarate (TDF) as components of regimens for treatment of patients coinfected with HIV and HBV4-6
- We report HBV and HIV outcomes in antiretroviral treatment (ART)-naïve and experienced HIV/HBV-coinfected patients enrolled in 2 studies of coformulated bictegravir/emtricitabine/TAF (B/F/TAF)
  - Active HBV infection = HBsAg positive or HBsAg negative, HBsAb negative, HBcAb positive with HBVDNA ≥ 20IU/mL on or prior to 1st dose date

RESULTS:

Study 1490 Results: HIV/HBV-Coinfected Treatment-Naïve Participants7

- 13/645 treatment-naïve participants had HIV/HBV at BL and HBV DNA results at Week 48
  - 11 (85%) achieved HBV DNA <29 IU/mL at Week 48
  - 2/13 participants (15%) had HBV DNA ≥29 IU/mL at Week 48
    - Both had HBV DNA >170,000,000 IU/mL at BL and were HBeAg positive
    - Week 48 HBV DNA results were 303 IU/mL and 80 IU/mL
  - 2/12 HBsAg+ participants (15%) experienced HBsAg loss: both seroconverted to HBsAb-positive status at Week 48
- All 13 participants had HIV-1 RNA <50 copies/mL at Week 48

Study 1878 Results: HIV/HBV-Co-infected Treatment-Experienced Participants

- Participants with active HBV infection were allowed to enroll in Study 1878.
- 14/577 participants (2%) had HIV/HBV coinfection at BL were randomized and treated; 2 participants discontinued treatment unrelated to study drug and did not have Week 48 HBV DNA assessments.
- All 12 participants with Week 48 data had HIV-1 RNA <50 copies/mL at Week 48

<table>
<thead>
<tr>
<th>HBV DNA &lt;29 IU/mL, n/n (%)</th>
<th>B/F/TAF, n=8</th>
<th>SBR, n=6</th>
</tr>
</thead>
<tbody>
<tr>
<td>BL</td>
<td>8</td>
<td>4</td>
</tr>
<tr>
<td>Week 48</td>
<td>8/8 (100)</td>
<td>4/4 (100)</td>
</tr>
</tbody>
</table>

CONCLUSIONS/IMPLICATIONS:

- B/F/TAF- and F/TAF-containing regimens produced robust HBV antiviral responses in treatment-naïve participants with HIV/HBV coinfection
  - 85% of participants (11/13) achieved HBV DNA <29 IU/mL at Week 48
  - No participant developed HBV resistance to FTC or TAF
  - 100% had HIV-1 RNA <50 copies/mL at Week 48
- B/F/TAF- and F/TDF-containing regimens maintained HIV-1 virologic suppression in HIV/HBV-coinfected participants with HIV-1 suppression at study entry
- No participant treated with B/F/TAF, or an F/TAF- or F/TDF containing regimen acquired HBV infection during the studies
- The results confirm findings from prior studies of ART with anti-HBV activity in patients with HIV/HBV coinfection
  - Higher HBsAb seroconversion rates than in chronic HBV mono-infection^8
  - Not all patients become undetectable after 48 weeks in the setting of high HBV DNA at baseline^9
    - To date, there is no evidence of HBV resistance to F/TAF-containing regimens
- B/F/TAF may be a treatment option for HIV-1–infected patients with HBV coinfection
  - Further studies of HBV treatment and prevention with B/F/TAF and other F/TAF-containing ART regimens are warranted in HIV/HBV-coinfected patients